Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Drug

AstraZeneca’s Calquence Approved by NMPA for Chronic Lymphocytic Leukemia Treatment

Fineline Cube Sep 4, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received another indication...

Company Drug

Roche’s Alecensa Achieves Milestone in Adjuvant Therapy Trial for Early-Stage NSCLC

Fineline Cube Sep 4, 2023

Switzerland-based pharmaceutical giant Roche (SWX: ROG) has released an update from an interim analysis of...

Company Deals Legal / IP

Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition

Fineline Cube Sep 4, 2023

Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with...

Company Drug

Japan’s MHLW Reviews GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps Indication

Fineline Cube Sep 4, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has begun the review process...

Company Drug

Eli Lilly’s Verzenios Receives NMPA Approval for Extended Indication in Early-Stage Breast Cancer

Fineline Cube Sep 4, 2023

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has announced that the National Medical...

Company Deals

Shanghai Biotech Cataya Secures $35 Million in Series B Financing for Synthetic Biology

Fineline Cube Sep 4, 2023

Shanghai-based biotech company Cataya, which specializes in synthetic biology, has reportedly raised RMB 250 million...

Company Drug

Shanghai Junshi Biosciences’ JS207 Bispecific Antibody Receives NMPA Clinical Trial Approval

Fineline Cube Sep 4, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Deals

XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development

Fineline Cube Sep 4, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...

Company Drug

United Laboratories’ UBT251 Receives Tacit Approval for Obesity Clinical Study in China

Fineline Cube Sep 4, 2023

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1...

Company Drug

Zai Lab’s Margenza (Margetuximab) Approved by China’s NMPA for HER2-Positive Breast Cancer

Fineline Cube Sep 4, 2023

The National Medical Products Administration (NMPA) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB,...

Company Drug

MicuRx Pharmaceuticals Initiates Phase III Trial for MRX-4 in Complex Skin Infections

Fineline Cube Sep 4, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...

Company Deals

EOC Pharma Group and Nanopeptide Biotechnology Forge Partnership for siRNA Drug Development

Fineline Cube Sep 1, 2023

China-based EOC Pharma Group has announced a strategic partnership with fellow country siRNA firm, Nanopeptide...

Company Medical Device

Rapid Medical’s Tigertriever Receives Chinese Approval as Adjustable Thrombectomy Device

Fineline Cube Sep 1, 2023

Israel-based medical device company Rapid Medical has announced that its revascularization device, Tigertriever, has received...

Company Drug

Genexine’s Eftansomatropin Alfa Achieves Phase III Endpoints in Growth Hormone Deficiency Trial

Fineline Cube Sep 1, 2023

South Korea-based Genexine (KOSDAQ: 095700) has announced that its long-acting growth hormone product candidate, eftansomatropin...

Company Deals

Huadong Medicine Secures Exclusive Rights to MC2 Therapeutics’ Plaque Psoriasis Therapy in China

Fineline Cube Sep 1, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2...

Company Deals

Innovac Therapeutics Secures $18 Million in Pre-Series A Financing for mRNA Vaccine Development

Fineline Cube Sep 1, 2023

Innovac Therapeutics, a Massachusetts-based mRNA vaccine developer, has announced the successful completion of its Pre-Series...

Company Drug

AstraZeneca’s Soliris Gains Approval for Pediatric Generalized Myasthenia Gravis in Japan

Fineline Cube Sep 1, 2023

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received an...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Earns Two BTDs for HER2+ Malignancies

Fineline Cube Sep 1, 2023

The US Food and Drug Administration (FDA) has granted AstraZeneca (AZ; NASDAQ: AZN) and Daiichi...

Company Drug

Bayer Funds Landmark Trials for Kerendia in Heart Failure Treatment Expansion

Fineline Cube Sep 1, 2023

Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed...

Company Drug

EMA and FDA Review AbbVie’s Skyrizi for Ulcerative Colitis Indication Extension

Fineline Cube Sep 1, 2023

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted...

Posts pagination

1 … 430 431 432 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.